While the Trump administration’s latest executive order touts sweeping drug price cuts through international benchmarking, ...

Ivo Abraham, PhD, highlights follow-on biologics as a pathway to a more equitable global health care system by reducing costs ...

Australia’s growing reliance on high-cost biologics for inflammatory skin diseases has placed significant pressure on its ...

Patients with rheumatoid arthritis (RA) who switched from Enbrel (reference etanercept) to a biosimilar maintained remission, ...

Number 5: Patients with rheumatoid arthritis (RA) who switched from Enbrel (reference etanercept) to a biosimilar maintained remission, even after their dose was reduced, with no signs of worsening ...

Biosimilar Approvals Streamlined With Advanced Statistics Amidst Differing Regulatory Requirements ...